TY - JOUR A1 - Petykó, Zsuzsanna Ida A1 - Kaló, Zoltán A1 - Espin, Jaime A1 - Podrazilová, Kateřina A1 - Tesař, Tomáš A1 - Maniadakis, Nikos A1 - Fricke, Frank-Ulrich A1 - Inotai, András T1 - Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings JF - Cost Effectiveness and Resource Allocation N2 - Background Medicines that are based on known molecules and are further developed to address healthcare needs and deliver relevant improvement for patients, healthcare professionals and/or payers are called value-added medicines (VAMs). The evaluation process of VAMs is heterogeneous across countries, and it has been primarily designed for originator pharmaceuticals with confirmatory evidence collected alongside pivotal clinical trials. There is a mismatch between evidence requirements by public decision-makers and evidence generated by manufacturers of VAMs. Our objective was to develop a core evaluation framework for VAMs. Methods Potential benefits offered by VAMs were collected through a systematic literature review and allocated to separate domains in an iterative process. The draft list of domains and their applicability were validated during two consecutive virtual workshops by health policy experts representing countries with different economic statuses, geographical and decision-making Y1 - 2021 U6 - https://doi.org/10.1186/s12962-021-00311-6 SN - 1478-7547 VL - 19 IS - 1 PB - Springer Science and Business Media LLC ER -